Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mahrukh

Showing results (541-550 of 560) with videos related to

Pageof 56
Sort By:
Lancet (London, England)|May 14, 2019
Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trialBrian I Rini, Thomas Powles, Michael B Atkins, et al.
British Journal of Anaesthesia|February 8, 2024
Intraoperative pharmacologic opioid minimisation strategies and patient-centred outcomes after surgery: a scoping reviewMichael Verret, Nhat H Lam, Manoj Lalu, et al.
Nature|February 28, 2020
Peripheral T cell expansion predicts tumour infiltration and clinical responseThomas D Wu, Shravan Madireddi, Patricia E de Almeida, et al.
Nature Medicine|October 7, 2018
Publisher Correction: Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinomaDavid F McDermott, Mahrukh A Huseni, Michael B Atkins, et al.
Nature Medicine|June 6, 2018
Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinomaDavid F McDermott, Mahrukh A Huseni, Michael B Atkins, et al.
Cell Reports. Medicine|January 4, 2023
CD8<sup>+</sup> T cell-intrinsic IL-6 signaling promotes resistance to anti-PD-L1 immunotherapyMahrukh A Huseni, Lifen Wang, Joanna E Klementowicz, et al.
Cancer|November 10, 2024
A comparison of isolated limb infusion/perfusion, immune checkpoint inhibitors, and intralesional therapy as first-line treatment for patients with melanoma in-transit metastasesDanielle K DePalo, Michelle M Dugan, Syeda Mahrukh Hussnain Naqvi, et al.
Vox Sanguinis|March 9, 2022
International Society of Blood Transfusion survey of experiences of blood banks and transfusion services during the COVID-19 pandemicArwa Z Al-Riyami, Thierry Burnouf, Erica M Wood, et al.
Journal for Immunotherapy of Cancer|August 24, 2022
Outcomes with adjuvant anti-PD-1 therapy in patients with sentinel lymph node-positive melanoma without completion lymph node dissectionZeynep Eroglu, Kristy K Broman, John F Thompson, et al.
Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie|October 26, 2020
Overestimation of Postpartum Depression Prevalence Based on a 5-item Version of the EPDS: Systematic Review and Individual Participant Data Meta-analysisBrett D Thombs, Brooke Levis, Anita Lyubenova, et al.
Pageof 56

Showing results (541-550 of 560) with videos related to

Sort By:
Pageof 56
Lancet (London, England)|May 14, 2019
Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trialBrian I Rini, Thomas Powles, Michael B Atkins, et al.
British Journal of Anaesthesia|February 8, 2024
Intraoperative pharmacologic opioid minimisation strategies and patient-centred outcomes after surgery: a scoping reviewMichael Verret, Nhat H Lam, Manoj Lalu, et al.
Nature|February 28, 2020
Peripheral T cell expansion predicts tumour infiltration and clinical responseThomas D Wu, Shravan Madireddi, Patricia E de Almeida, et al.
Nature Medicine|October 7, 2018
Publisher Correction: Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinomaDavid F McDermott, Mahrukh A Huseni, Michael B Atkins, et al.
Nature Medicine|June 6, 2018
Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinomaDavid F McDermott, Mahrukh A Huseni, Michael B Atkins, et al.
Cell Reports. Medicine|January 4, 2023
CD8<sup>+</sup> T cell-intrinsic IL-6 signaling promotes resistance to anti-PD-L1 immunotherapyMahrukh A Huseni, Lifen Wang, Joanna E Klementowicz, et al.
Cancer|November 10, 2024
A comparison of isolated limb infusion/perfusion, immune checkpoint inhibitors, and intralesional therapy as first-line treatment for patients with melanoma in-transit metastasesDanielle K DePalo, Michelle M Dugan, Syeda Mahrukh Hussnain Naqvi, et al.
Vox Sanguinis|March 9, 2022
International Society of Blood Transfusion survey of experiences of blood banks and transfusion services during the COVID-19 pandemicArwa Z Al-Riyami, Thierry Burnouf, Erica M Wood, et al.
Journal for Immunotherapy of Cancer|August 24, 2022
Outcomes with adjuvant anti-PD-1 therapy in patients with sentinel lymph node-positive melanoma without completion lymph node dissectionZeynep Eroglu, Kristy K Broman, John F Thompson, et al.
Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie|October 26, 2020
Overestimation of Postpartum Depression Prevalence Based on a 5-item Version of the EPDS: Systematic Review and Individual Participant Data Meta-analysisBrett D Thombs, Brooke Levis, Anita Lyubenova, et al.
Pageof 56